Dealing with industry’s influence on clinical evidence

I co-wrote a piece for The Conversation about a new article that was published in the Cochrane Database of Systematic Reviews, written by Andreas Lundh and other luminaries from the research area. The authors showed that industry sponsored clinical trials more often report positive outcomes and fewer harmful side effects. The most interesting result from … Continue reading Dealing with industry’s influence on clinical evidence

How long does it take for new prescription drugs to become mainstream?

You probably don’t want to hear your doctor proclaiming “I’m so indie, I was prescribing that *way* before it was cool.” Or maybe you do? If you’re a hipster and you really need to know when a particular band stops being underground and teeters on the edge of being mainstream so you can only like … Continue reading How long does it take for new prescription drugs to become mainstream?

Learning from “Learning from Hackers”

Alongside colleagues (Enrico Coiera and Richard Day) from here in Sydney and (Kenneth Mandl) from near Boston in the US, I wrote an article for Science Translational Medicine in which we related the current system of “clinical trial evidence translation” to the very successful open source software movement. We highlighted the factors in that success - … Continue reading Learning from “Learning from Hackers”

Repost: Pharma’s influence over published clinical evidence

Below is a copy of an article I wrote for The Conversation. It’s an independent source of information and analysis about things that matter - but from the university and research perspective, which means it’s generally more rigorous than much of the rest. This article was originally published at The Conversation. Read the original article.   TRANSPARENCY … Continue reading Repost: Pharma’s influence over published clinical evidence

Do pharmaceutical companies have too much influence over the evidence base?

Imagine you are a doctor and you have a patient sitting with you in your office. You have already diagnosed your patient with a condition. Treatment for this condition will definitely include prescribing the patient with one or more drugs. And, because the condition is quite common, there are several government-subsidised drugs from which you … Continue reading Do pharmaceutical companies have too much influence over the evidence base?

Financial conflicts of interest in guidelines

A new study published in the BMJ shows the prevalence of financial conflicts of interest in the panel members producing clinical guidelines. For consumers of healthcare delivery (that means everyone), I think it is valuable to know that doctors get their information from guidelines, and about half of the people developing those guidelines have financially-based … Continue reading Financial conflicts of interest in guidelines